Astrazeneca plc, of London, reported full results from the PEGASUS-TIMI 54 outcomes trial, which enrolled more than 21,000 to study Brilinta (ticagrelor) tablets plus low-dose aspirin compared to placebo plus low-dose aspirin, for the treatment of chronic secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study enrollment.